Mounjaro has a list price of $1,112.16 for a one-month supply, which includes four injectable pens. That’s the wholesale price Eli Lilly charges before insurance, coupons, or any other discounts. What you actually pay can range from as little as $25 per month to the full list price or more, depending on your insurance, your diagnosis, and which savings programs you qualify for.
List Price vs. What You Actually Pay
The $1,112.16 figure is the same regardless of your dose. Whether your prescription is for 2.5 mg (the starting dose) or 15 mg (the highest), Lilly prices every strength identically at the wholesale level. This is the baseline number pharmacies work from, but it rarely reflects what lands on your receipt.
If you have commercial insurance that covers Mounjaro, your copay will depend on your plan’s formulary tier, deductible, and coinsurance structure. Some plans place it on a specialty tier with higher cost-sharing; others negotiate it down to a preferred brand copay. The range is wide, from under $50 to several hundred dollars per month. If your plan doesn’t cover it at all and you’re paying cash at a retail pharmacy, expect to pay close to that $1,112 list price plus any dispensing fees.
The Manufacturer Savings Card
Eli Lilly offers a Mounjaro Savings Card that can drop your cost to as little as $25 for a one-month or three-month supply. The catch: you need commercial (private) insurance. The card is designed to offset your copay or coinsurance after your insurer processes the claim. It does not work for people on Medicare, Medicaid, or other government-funded insurance programs, and it’s not available to uninsured patients.
If you have commercial coverage and your plan covers Mounjaro for type 2 diabetes, this savings card is the single biggest cost reducer available. Eligibility terms can change, so check the current offer through Lilly’s website or your prescriber’s office before filling.
Zepbound Vials: A Lower-Cost Alternative
Mounjaro is approved for type 2 diabetes. Its sister drug Zepbound uses the same active ingredient (tirzepatide) but is approved for weight management. If your prescription is for weight loss rather than diabetes, Lilly offers Zepbound single-dose vials at significantly lower self-pay prices through its LillyDirect platform.
The pricing breaks down by dose: $349 per month for 2.5 mg, $499 for 5 mg, $599 for 7.5 mg, and $699 for 10 mg. Through the Zepbound Self Pay Journey Program, the 7.5 mg and 10 mg vials drop to $499 on your first fill and on refills placed within 45 days of your previous delivery. If you refill outside that window, you pay the higher price. These vials require you to draw the medication with a syringe rather than using a pre-filled pen, and they’re only available through LillyDirect’s self-pay pharmacy, not at retail chains.
This option exists specifically for people paying out of pocket. It’s worth discussing with your prescriber if you don’t have insurance coverage for either Mounjaro or Zepbound and cost is a barrier.
Insurance Coverage and Prior Authorization
Most commercial insurers cover Mounjaro for type 2 diabetes, but almost all require prior authorization before they’ll pay. That means your doctor has to submit paperwork proving you meet specific clinical criteria. The exact requirements vary by insurer, but a typical policy looks like this: you need a confirmed diabetes diagnosis (usually based on an A1C of 6.5% or higher), you need to have tried and failed on preferred medications like metformin first, and your blood sugar levels need to be above a certain threshold if you’re adding Mounjaro to existing treatment.
Approval periods typically last 12 months before your doctor needs to reauthorize. Each fill is limited to four pens or vials per 28 days. If your prior authorization is denied, your prescriber can often appeal with additional documentation, but the process can take days to weeks.
For weight loss specifically, coverage is much harder to get. Many commercial plans exclude weight management drugs entirely. If your insurer does cover weight loss medications, they’ll generally steer you toward Zepbound (the weight-loss-labeled version) rather than Mounjaro.
Medicare and Mounjaro
Medicare Part D currently covers Mounjaro only for type 2 diabetes, not for weight loss. Coverage for weight management drugs under Medicare has historically been excluded by law, though that landscape is shifting.
Starting in July 2026, CMS is launching the Medicare GLP-1 Bridge, a temporary demonstration program running through the end of 2027. This program will cover certain GLP-1 drugs for weight reduction, but only Zepbound, Wegovy, and Foundayo are eligible. Mounjaro is not on the list. To qualify, beneficiaries will need a BMI of 35 or higher, or a BMI of 30 or higher with conditions like uncontrolled high blood pressure, heart failure, or chronic kidney disease, or a BMI of 27 or higher with a history of heart attack, stroke, or pre-diabetes.
If you’re on Medicare and using Mounjaro for diabetes, your Part D plan may cover it, but your out-of-pocket cost depends on your plan’s formulary and which coverage phase you’re in. During the deductible phase or the coverage gap, costs can be substantial.
Ways to Lower Your Cost
Your best option depends on your insurance situation:
- Commercial insurance with coverage: Use the Mounjaro Savings Card to potentially pay as little as $25 per month.
- Commercial insurance without coverage: Ask your doctor to submit a prior authorization or appeal. If your plan still won’t cover it, you’re effectively in the same position as an uninsured patient.
- No insurance or paying cash: If your prescription is for weight management, Zepbound vials through LillyDirect start at $349 per month. For diabetes, pharmacy discount tools like Optum Perks or GoodRx coupons may reduce the retail price somewhat, though the savings won’t be as dramatic. These coupons cannot be combined with insurance benefits.
- Medicare: Check whether your Part D plan covers Mounjaro for diabetes. For weight loss, the Medicare GLP-1 Bridge program beginning in mid-2026 may offer coverage for Zepbound, though not for Mounjaro itself.
Lilly does not currently offer a patient assistance program for uninsured patients specifically for Mounjaro. The savings card is limited to those with commercial coverage, which leaves self-pay patients facing the full list price at retail pharmacies unless they can switch to the Zepbound vial option.